aspirin and Cardiac Diseases studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

Excerpt	Relevance	Reference
"To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes."	9.34	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."	9.13	The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"Warfarin is effective in preventing thromboembolism in patients with atrial fibrillation, but aspirin is frequently used as an alternative treatment."	9.09	[Risk factors for thromboembolism in patients with atrial fibrillation during treatment with aspirin: a multicenter, cooperative retrospective study. Research Group for Antiarrhythmic Drug Therapy]. ( , 2000)
"This study aimed to evaluate a new platelet assay (Anysis-aspirin), compare it with VerifyNow-aspirin in patients with cardiac diseases, and analyze the aspirin resistance rates between the two devices."	8.02	Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases. ( Choi, CU; Kim, S; Piao, J; Shin, S; Whang, YW; Yoo, C, 2021)
"The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge management on the incidence of left ventricular (LV) thrombus in patients with first acute anterior ST elevation myocardial infarction (STEMI)."	7.91	The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. ( Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B, 2019)
"Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings."	7.75	Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009)
" The patient had decided to take low-molecular-weight heparin (LMWH) and aspirin throughout her pregnancy."	7.74	Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. ( Curtis, SL; Stuart, AG; Trinder, J, 2008)
"Patients with atrial fibrillation taking either indirect anticoagulant acenocumarol or most often prescribed antiaggregant aspirin were followed for 1 year."	7.74	[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation]. ( Ataullakhanova, DM; Bykova, ES; Dobrovol'skiĭ, AB; Kropacheva, ES; Panchenko, EP; Titaeva, EV; Zharkova, TV, 2007)
"The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established."	7.70	Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000)
"To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes."	5.34	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."	5.13	The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"Warfarin is effective in preventing thromboembolism in patients with atrial fibrillation, but aspirin is frequently used as an alternative treatment."	5.09	[Risk factors for thromboembolism in patients with atrial fibrillation during treatment with aspirin: a multicenter, cooperative retrospective study. Research Group for Antiarrhythmic Drug Therapy]. ( , 2000)
" Randomized trials have found that in specific patient subgroups, tamoxifen and raloxifene decreased the occurrence of breast cancer, and lovastatin and aspirin decreased the frequency of CAD events."	4.80	Preventing heart disease and cancer. What randomized, primary-prevention studies show. ( Lush, DT, 1999)
"This study aimed to evaluate a new platelet assay (Anysis-aspirin), compare it with VerifyNow-aspirin in patients with cardiac diseases, and analyze the aspirin resistance rates between the two devices."	4.02	Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases. ( Choi, CU; Kim, S; Piao, J; Shin, S; Whang, YW; Yoo, C, 2021)
"The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge management on the incidence of left ventricular (LV) thrombus in patients with first acute anterior ST elevation myocardial infarction (STEMI)."	3.91	The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. ( Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B, 2019)
" In this study, taking advantage of the transparency of larval zebrafish, Danio rerio, we assessed cardiovascular toxicity of seven known human cardiotoxic drugs (aspirin, clomipramine hydrochloride, cyclophosphamide, nimodipine, quinidine, terfenadine and verapamil hydrochloride) and two non-cardiovascular toxicity drugs (gentamicin sulphate and tetracycline hydrochloride) in zebrafish using six specific phenotypic endpoints: heart rate, heart rhythm, pericardial edema, circulation, hemorrhage and thrombosis."	3.80	Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. ( Dong, QX; Gao, JM; He, JH; Huang, CJ; Li, CQ; Xu, YQ; Xuan, YX; Yu, HP; Zhu, JJ, 2014)
"Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings."	3.75	Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009)
"Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA."	3.75	Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982)
" The patient had decided to take low-molecular-weight heparin (LMWH) and aspirin throughout her pregnancy."	3.74	Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. ( Curtis, SL; Stuart, AG; Trinder, J, 2008)
"We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)."	3.74	Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008)
"Patients with atrial fibrillation taking either indirect anticoagulant acenocumarol or most often prescribed antiaggregant aspirin were followed for 1 year."	3.74	[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation]. ( Ataullakhanova, DM; Bykova, ES; Dobrovol'skiĭ, AB; Kropacheva, ES; Panchenko, EP; Titaeva, EV; Zharkova, TV, 2007)
" 2 patients who were treated with concomitant warfarin had bleeding complications (severe epistaxis and gastrointestinal bleeding)."	3.74	Safety and efficacy of clopidogrel in children with heart disease. ( Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008)
"In general, aspirin is indicated to prevent thrombosis in conditions associated with high shear rates (i."	3.70	Warfarin or aspirin: both or others? ( Peverill, RE, 1999)
"The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established."	3.70	Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000)
" The purpose of the present study was to examine the formation and resolution of left ventricular thrombi during the first month in patients with acute anterior myocardial infarction treated with streptokinase and aspirin."	3.69	Dynamics of left ventricular thrombi in patients with acute anterior myocardial infarction treated with thrombolytics. ( Eriksson, P; Karp, KH; Mooe, T; Teien, DE, 1995)
"With routine thrombolytic and aspirin treatment of anterior myocardial infarction, left ventricular thrombi usually resolve during the first month after hospital discharge."	3.69	Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era. ( Eriksson, P; Karp, K; Mooe, T; Teien, D, 1996)
"Myocardial infarction was assessed using the third universal definition."	2.82	Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study. ( Beattie, WS; Carroll, J; Grewal, D; Harsha, P; Karkouti, K; Ragoonanan, T; Starzyk, Ł; Syed, S; Travis, G; Wąsowicz, M; Wijeysundera, DN, 2016)
"Abciximab produced a 58% reduction in thrombus formation (11,631 +/- 861 vs 4, 925 +/- 585 microm(2); p <0."	2.69	Antithrombotic effects of abciximab. ( Badimon, JJ; Badimon, L; Chesebro, JH; Coller, BS; Dangas, G; Fallon, JT; Fuster, V; Hayes, R; Marmur, JD; Sharma, SK, 2000)
"Patients with asymptomatic internal carotid artery stenosis exceeding 60% reduction in diameter who are acceptable candidates for elective operation may be considered for CEA if the combined arteriographic and surgical complication rates are 3% or less."	2.68	An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. ( Broderick, JP; Cohen, SN; Dempsey, RJ; Ernst, CB; Hosking, JD; Moore, WS; Robertson, JT; Toole, JF; Young, B, 1996)
"LV thrombosis was found in 37 (27."	2.67	Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy. ( Dale, J; Hegrenaes, L; Kontny, F; Lem, P; Morstøl, T; Søberg, T, 1993)
"Kawasaki disease is an acute, self-limited vasculitis of childhood."	2.44	Kawasaki disease: an overview. ( Kafetzis, DA; Pinna, GS; Skevaki, CL; Tselkas, OI, 2008)
" In addition, obtaining a valid therapeutic activated partial thromboplastin time (aPTT) in cardiology patients is a major challenge, and dosing is complex."	2.42	Unfractionated heparin in cardiology: redefining the standard of practice. ( Díez, J; Rihn, TL, 2004)
"Kawasaki disease is the leading cause of acquired heart disease in childhood."	2.41	Long-term cardiac sequelae of Kawasaki disease. ( Fulton, DR; Newburger, JW, 2000)
" A survey of the currently available blood conservation techniques reveals 5 that stand out as reliable methods: 1) high-dose aprotinin therapy, 2) preoperative erythropoietin therapy when time permits adequate dosage before operation, 3) hemodilution by harvest of whole blood immediately before cardiopulmonary bypass, 4) autologous predonation of blood, and 5) salvage of oxygenator blood after cardiopulmonary bypass."	2.39	Limiting excessive postoperative blood transfusion after cardiac procedures. A review. ( Ferraris, SP; Ferraris, VA, 1995)
"Kawasaki syndrome was first described in 1967 in Japan."	2.38	[Kawasaki syndrome]. ( Odermatt, K; Schaad, UB; Stocker, FP; Weber, JW; Wedgwood, J, 1990)
"Kawasaki Syndrome is a newly recognized clinical entity characterized by multisystem involvement."	2.36	Kawasaki syndrome (the mucocutaneous lymph node syndrome). ( Melish, ME, 1982)
"Few data are currently available for Kawasaki disease (KD) below 12 months especially in Caucasians."	1.51	Kawasaki disease in infants less than one year of age: an Italian cohort from a single center. ( Calabri, GB; Cimaz, R; Lasagni, D; Mastrangelo, G; Resti, M; Simonini, G; Trapani, S, 2019)
"We report cerebral embolism in 2 patients with Duchenne muscular dystrophy (DMD) after respiratory tract infection."	1.48	[Cerebral embolism in Duchenne muscular dystrophy after respiratory tract infection - Report of two cases]. ( Fujimura, H; Hasuike, Y; Matsumura, T; Saito, T; Sakoda, S, 2018)
"The diagnosis of Kawasaki disease must be raised when predisposing factors are present in this group."	1.37	[Kawasaki disease in older children and young adults: 10 years of experience in Marseille, France]. ( Bonello, B; Bosdure, E; Bresson, V; Chabrol, B; Dubus, JC; Rousset-Rouvière, C; Serratrice, J, 2011)
" All patient groups were similar regarding age, gender distribution, dosage of antiplatelet drug, and medical condition for which the drug was prescribed."	1.35	Exodontia and antiplatelet therapy. ( Alexander, M; Krishnan, B; Shenoy, NA, 2008)
"We report a case of apical thrombus formation among a group of 15 patients with takotsubo cardiomyopathy who were referred for a suspected acute coronary syndrome over a 2."	1.35	Apical thrombus in a patient with takotsubo cardiomyopathy. ( Amico, F; Argentino, V; Azzarelli, S; Fiscella, A; Galassi, AR; Giacoppo, M; Giordano, G, 2008)
"Myocarditis and dilated cardiomyopathy is characterized by dilatation of all four cardiac chambers and decreased systolic function of the heart, especially in the left ventricle."	1.34	Treatment of massive cardiac thrombi in a patient with protein C and protein S deficiency. ( Cağdaş, DN; Paç, FA, 2007)
"Kawasaki disease is an acute self-limited vasculitis of childhood that is characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy."	1.32	Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004)
"Kawasaki disease is an acute self-limited vasculitis of childhood that is characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy."	1.32	Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004)
"LA thrombus was present in 18% (n = 46) and LA spontaneous echocardiographic contrast in 50% (n = 131) of the group."	1.32	Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. ( Dawn, B; Longaker, RA; Singh, P; Stoddard, MF, 2003)
"Here we report two cases of Kawasaki disease both of whom had a benign course."	1.31	Kawasaki disease--Indian perspective. ( Bhandari, B; Bhandari, H; Pendse, RN; Vats, AK, 2001)
"A fresh mural thrombus was formed by perfusing severely injured arterial wall with porcine blood for 5 minutes at a shear rate of 1690 s(-1)."	1.30	Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. ( Badimon, JJ; Badimon, L; Chesebro, JH; Fallon, JT; Fuster, V; Meyer, BJ, 1998)
"Among 801 patients not receiving treatment for thromboembolism, the annual rate was 0."	1.30	[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy]. ( , 1998)
"Lesions with thrombus formation were found in four animals in the heparin/aspirin group and in nine animals in the control group."	1.29	Power and temperature guided radiofrequency catheter ablation of the right atrium in pigs. ( Aass, H; Amlie, JP; Foerster, A; Kongsgaard, E; Madsen, S, 1994)
"The embolic risk and changes of thrombus location and size were investigated in 29 consecutive patients with echocardiographically proven thrombi in the left atrium."	1.29	[Transthoracic and transesophageal follow-up in patients with left atrial thrombosis]. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, R, 1994)
"At reexamination, one thrombus was detected in the patient without anticoagulant treatment and one thrombus was detected in the 8 patients treated with aspirin (13%), compared with ten thrombi detected in the 20 patients (50%) treated with phenprocoumon (p = NS)."	1.29	Left atrial thrombi despite anticoagulant and antiplatelet therapy. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, RJ, 1994)
"Aspirin was usually chosen after initial brain ischemia."	1.29	Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. ( Furlan, AJ; Hanna, JP; Sila, CA; Stewart, WJ; Sun, JP; Tan, M, 1994)
"He developed bronchial asthma at 41 years of age."	1.28	[A case of hypereosinophilic syndrome followed by bronchial asthma, intraventricular thrombus, and duodenitis]. ( Aoi, K; Doi, I; Hiraga, T; Kawakami, Y; Munakata, M; Ohtsuka, Y, 1991)
"Platelet-thrombus formation is a complication of arterial wall deep injury by balloon angioplasty that may lead to acute arterial occlusion and may contribute to restenosis."	1.28	Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. ( Badimon, L; Chesebro, JH; Fuster, V; Heras, M; Lam, JY; Steele, PM; Webster, MW, 1991)
"Although the etiology of Kawasaki syndrome remains poorly understood, new evidence points to an inherited defect in T-lymphocyte immunoregulation."	1.28	Kawasaki syndrome: still a fascinating enigma. ( Barron, KS; Murphy, DJ, 1989)
"First reported in Japan in 1967, Kawasaki disease appeared in Virginia this year."	1.26	Kawasaki disease is diagnosed in Virginia. ( Kesler, RW; Lohr, JA, 1978)

Research

Studies (213)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

All-cause Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	33 (15.49)	18.7374
1990's	42 (19.72)	18.2507
2000's	85 (39.91)	29.6817
2010's	46 (21.60)	24.3611
2020's	7 (3.29)	2.80

Authors	Studies
Kuo, NC	1
Lin, CH	1
Lin, MC	1
Mastrangelo, G	1
Cimaz, R	2
Calabri, GB	1
Simonini, G	1
Lasagni, D	1
Resti, M	1
Trapani, S	1
Perera, KS	1
Ng, KKH	1
Nayar, S	1
Catanese, L	1
Dyal, L	1
Sharma, M	1
Connolly, SJ	1
Yusuf, S	2
Bosch, J	1
Eikelboom, JW	2
Hart, RG	2
Hardung, D	1
Behne, A	1
Langhoff, R	1
Rose, DS	1
Robinson, B	1
Kannan, S	1
Lee, JC	1
Wu, XT	1
He, RR	1
Liang, SZ	1
Ye, GY	1
Ding, SB	1
Murphey, AC	1
Morrison Ponce, D	1
Hashikawa, AN	1
Dannenberg, L	1
M'Pembele, R	1
Mourikis, P	1
Helten, C	1
Zako, S	1
Ahlbrecht, S	1
Richter, H	1
Zikeli, D	1
Benkhoff, M	1
Huhn-Wientgen, R	1
Thienel, M	1
Levkau, B	1
Kelm, M	1
Petzold, T	1
Polzin, A	1
Piao, J	1
Yoo, C	1
Kim, S	1
Whang, YW	1
Choi, CU	1
Shin, S	1
Baschin, M	1
Selleng, S	1
Hummel, A	1
Diedrich, S	1
Schroeder, HW	1
Kohlmann, T	1
Westphal, A	1
Greinacher, A	1
Thiele, T	1
Tang, QJ	1
Lei, HP	1
Wu, H	1
Chen, JY	1
Deng, CY	1
Sheng, WS	1
Fu, YH	1
Li, XH	1
Lin, YB	1
Han, YL	1
Zhong, SL	1
Hasuike, Y	1
Saito, T	2
Matsumura, T	1
Fujimura, H	1
Sakoda, S	1
Masjuan, J	1
Salido, L	1
DeFelipe, A	1
Hernández-Antolín, R	1
Fernández-Golfín, C	1
Cruz-Culebras, A	1
Matute, C	1
Vera, R	1
Pérez-Torre, P	1
Zamorano, JL	1
Shah, R	1
Khan, SA	1
Khan, B	1
Latham, SB	1
Dillinger, JG	1
Henry, P	1
Altıntaş, B	1
Altındağ, R	1
Bilge, Ö	1
Baysal, E	1
Öztürk, Ö	1
Yaylak, B	1
Ede, H	1
Karahan, MZ	1
Burak, C	1
Tanboğa, İH	1
Chen, Z	1
Qian, J	1
Chen, Y	1
Ma, J	1
Ge, J	1
Sherrod, MM	1
Sherrod, NM	1
Spitzer, MT	1
Cheek, DJ	1
Petricevic, M	2
Biocina, B	2
Konosic, S	1
Burcar, I	1
Scherner, M	1
Hekmat, K	1
Madershahian, N	1
Hellmich, M	1
Wahlers, T	1
Sun, J	2
Young, N	2
Liu, H	2
Yao, L	1
Silvestry, S	2
Sun, W	2
Zhao, N	2
Diehl, J	2
D'Silva, A	1
Jassim, I	1
Greenwood, J	1
Grosser, K	1
Cattaneo, M	1
Ottani, F	1
Lackland, DT	1
Roccella, EJ	1
Deutsch, AF	1
Fornage, M	1
George, MG	1
Howard, G	1
Kissela, BM	1
Kittner, SJ	1
Lichtman, JH	1
Lisabeth, LD	1
Schwamm, LH	1
Smith, EE	1
Towfighi, A	1
Mendiz, OA	1
Fava, CM	1
Lev, GA	1
Valdivieso, LR	1
Caponi, G	1
Hidalgo Alava, GF	1
Favaloro, RR	1
Komaroff, AL	2
Abraham, NS	1
Heinzl, S	1
Capodanno, D	1
Musumeci, G	1
Lettieri, C	1
Limbruno, U	1
Senni, M	1
Guagliumi, G	1
Valsecchi, O	1
Angiolillo, DJ	1
Rossini, R	1
Wąsowicz, M	1
Syed, S	1
Wijeysundera, DN	1
Starzyk, Ł	1
Grewal, D	1
Ragoonanan, T	1
Harsha, P	1
Travis, G	1
Carroll, J	1
Karkouti, K	1
Beattie, WS	1
Lau, YC	1
Xiong, Q	1
Ranjit, P	1
Lip, GY	1
Blann, AD	1
Kashani, R	1
Bowles, C	1
Sareh, S	1
Toppen, W	1
Ou, R	1
Shemin, R	1
Benharash, P	1
Ozdemir, K	1
Aygül, N	1
Can, I	1
Aribaş, A	1
Mertens, L	1
Eyskens, B	1
Boshoff, D	1
Gewillig, M	1
Azzarelli, S	1
Galassi, AR	1
Amico, F	1
Giacoppo, M	1
Argentino, V	1
Giordano, G	1
Fiscella, A	1
Dropiński, J	1
Szczeklik, W	1
Sokołowska, B	1
Celińska-Lowenhoff, M	1
Milewski, M	1
Szczeklik, A	1
Krishnan, B	1
Shenoy, NA	1
Alexander, M	1
Selim, M	1
Mrdovic, I	1
Perunicic, J	1
Asanin, M	1
Matic, M	1
Vasiljevic, Z	1
Ostojic, M	1
Csiba, L	1
Kovács, KR	1
Saw, J	1
Densem, C	1
Walsh, S	1
Jokhi, P	1
Starovoytov, A	1
Fox, R	1
Wong, G	1
Buller, C	1
Ricci, D	1
Mancini, GB	1
Fung, A	1
Sorensen, SV	1
Dewilde, S	1
Singer, DE	1
Goldhaber, SZ	1
Monz, BU	1
Plumb, JM	1
De Schryver, EL	1
Algra, A	1
García-Rinaldi, R	1
Carro-Pagán, C	1
Schaff, HV	1
McKellar, SH	1
Thompson, JL	1
Quiñones, J	1
Rodríguez-Acosta, JF	1
Borrás, X	1
Murga, N	1
Fiol, M	1
Pedreira, M	1
Erdem, G	1
Geisler, T	1
Flather, MD	1
Aydinalp, A	1
Atar, I	1
Altin, C	1
Gülmez, O	1
Atar, A	1
Açikel, S	1
Bozbaş, H	1
Yildirir, A	1
Müderrisoğlu, H	1
Tapp, LD	1
Lip, GYH	1
Lane, DA	1
Zhao, HJ	1
Zheng, ZT	1
Wang, ZH	1
Li, SH	1
Zhang, Y	1
Zhong, M	1
Zhang, W	1
Nam, D	1
Lerakis, S	1
Fajt, ML	1
Petrov, AA	1
Bresson, V	1
Bonello, B	1
Rousset-Rouvière, C	1
Serratrice, J	1
Chabrol, B	1
Dubus, JC	1
Bosdure, E	1
Gasparovic, H	1
Cardona, L	1
Ana, G	1
Luísa, B	1
Leal, A	1
António, F	1
Lídia, S	1
Cruz, FR	1
Cao, L	1
Rassi, AN	1
Blackstone, E	1
Militello, MA	1
Theodos, G	1
Cavender, MA	1
Sun, Z	1
Ellis, SG	1
Cho, L	1
Schoenefeld, E	1
Donas, K	1
Radicke, A	1
Osada, N	1
Austermann, M	1
Torsello, G	1
Renda, G	1
de Caterina, R	1
Cappellano, G	1
Uberti, F	1
Caimmi, PP	1
Pietronave, S	1
Mary, DA	1
Dianzani, C	1
Micalizzi, E	1
Melensi, M	1
Boldorini, R	1
Nicosia, G	1
Crosio, E	1
Chiocchetti, A	1
Aina, F	1
Prat, M	1
Dianzani, U	1
Vacca, G	1
Ariatti, C	1
Grossini, E	1
Burkholder, GA	1
Tamhane, AR	1
Salinas, JL	1
Mugavero, MJ	1
Raper, JL	1
Westfall, AO	1
Saag, MS	1
Willig, JH	1
Zhu, JJ	1
Xu, YQ	1
He, JH	1
Yu, HP	1
Huang, CJ	1
Gao, JM	1
Dong, QX	1
Xuan, YX	1
Li, CQ	1
Fox, KA	1
Goodman, SG	1
Klein, W	1
Brieger, D	1
Steg, PG	1
Dabbous, O	1
Avezum, A	1
Waksman, R	1
Ajani, AE	1
Pinnow, E	1
Cheneau, E	1
Leborgne, L	1
Dieble, R	1
Bui, AB	1
Satler, LF	1
Pichard, AD	1
Kent, KK	1
Lindsay, J	1
Hall, M	1
McGettigan, M	1
O'Callaghan, P	1
Graham, I	1
Shelley, E	1
Feely, J	1
Sawhney, MS	1
Nelson, DB	1
Stoddard, MF	1
Singh, P	1
Dawn, B	1
Longaker, RA	1
Greiver, M	1
Collart, F	1
Derouck, D	1
Kerbaul, F	1
Feier, H	1
Mesana, TG	1
Harrington, RA	1
Hodgson, PK	1
Larsen, RL	1
Stiefelhagen, P	1
BUFF, IE	1
JENNINGS, GH	1
GILES, HM	1
Ridker, PM	2
Senior, K	1
Ohashi, N	1
Sumii, K	1
Inoue, R	1
Nakanishi, T	1
Gomyo, Y	1
Hwong, TM	1
Arifi, AA	1
Wan, IY	1
Thung, KH	1
Wan, S	1
Sung, RY	1
Yim, AP	1
Rihn, TL	1
Díez, J	1
Newburger, JW	3
Takahashi, M	2
Gerber, MA	2
Gewitz, MH	2
Tani, LY	2
Burns, JC	2
Shulman, ST	2
Bolger, AF	2
Ferrieri, P	2
Baltimore, RS	2
Wilson, WR	2
Baddour, LM	2
Levison, ME	2
Pallasch, TJ	2
Falace, DA	2
Taubert, KA	2
Grossmann, R	1
Sokolova, O	1
Schnurr, A	1
Bonz, A	1
Porsche, C	1
Obergfell, A	1
Lengenfelder, B	1
Walter, U	1
Eigenthaler, M	1
Walker, HA	1
Gatzoulis, MA	1
Sun, JC	1
Crowther, MA	1
Warkentin, TE	1
Lamy, A	1
Teoh, KH	1
Klinkhardt, U	1
Harder, S	1
Couzin, J	1
Piepoli, MF	1
Martin, CM	1
Almond, J	1
Haines, ST	1
Fuke, DC	1
Lender, D	1
Rodgers, PT	1
Sysko, SK	1
Feringa, HH	1
Bax, JJ	1
Schouten, O	1
Poldermans, D	1
Schmidt, M	1
Brömsen, J	1
Blumenstein, M	1
Jhund, P	1
McMurray, JJ	1
Mareev, VIu	1
Stef, G	1
Csiszar, A	1
Lerea, K	1
Ungvari, Z	1
Veress, G	1
Toyoda, K	1
Okada, Y	1
Ibayashi, S	1
Inoue, T	1
Yasumori, K	1
Fukui, D	1
Uwatoko, T	1
Makihara, N	1
Minematsu, K	1
Dyer, O	1
Tardin, FA	1
Avanza, AC	1
Andião, MR	1
Rabello, SM	1
Cristello, Ede M	1
Baltan, EC	1
Pegurin, EB	1
Oliveira, NS	1
Sullivan, JL	2
Spiess, BD	1
van der Linden, J	1
Patel, D	1
Moonis, M	1
Flipo, RM	1
Paç, FA	1
Cağdaş, DN	1
Sun, JZ	1
Maguire, D	1
Zeymer, U	1
Gitt, A	1
Jünger, C	1
Bauer, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]	Phase 3	27,395 participants (Actual)	Interventional	2013-02-28	Completed
Prospective Evaluation for Hybrid Cardiac Procedures[NCT05143671]		111 participants (Anticipated)	Observational	2021-05-13	Recruiting
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]		1,492 participants (Anticipated)	Observational [Patient Registry]	2019-08-01	Recruiting
The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery[NCT01707459]		201 participants (Actual)	Observational	2010-03-31	Completed
Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566]	Phase 4	624 participants (Actual)	Interventional	2004-12-31	Completed
Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease[NCT00760435]	Phase 3	196 participants (Actual)	Interventional	2009-03-31	Completed
Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667]		43 participants (Actual)	Interventional	2004-11-30	Completed
Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2[NCT03333590]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-11-06	Active, not recruiting
Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction[NCT05892042]		320 participants (Anticipated)	Interventional	2023-05-01	Recruiting
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665]		30 participants (Actual)	Interventional	2016-03-31	Completed
Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769]	Phase 1	9 participants (Actual)	Interventional	2017-06-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

All-cause Mortality in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	313
Rivaroxaban 5mg + Aspirin Placebo	366
Rivaroxaban Placebo + Aspirin 100mg	378

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	282

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	389
Rivaroxaban 5mg + Aspirin Placebo	453
Rivaroxaban Placebo + Aspirin 100mg	516

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	329
Rivaroxaban 5mg + Aspirin Placebo	397
Rivaroxaban Placebo + Aspirin 100mg	450

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	379
Rivaroxaban 5mg + Aspirin Placebo	448
Rivaroxaban Placebo + Aspirin 100mg	496

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	353

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	288
Rivaroxaban 5mg + Aspirin Placebo	255
Rivaroxaban Placebo + Aspirin 100mg	170

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

Change From Baseline in Left Anterior Descending Coronary Artery Outcomes at Week 2 by Treatment Arm

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	138

left anterior descending coronary artery Z-score; a Z score is the coronary artery adjusted for body surface area (NCT00760435)
Timeframe: 2 weeks

Change in C-reactive Protein (CRP) From Baseline at 24 Hours After Completion of Intravenous Immunoglobulin (IVIG) by Study Arm.

Number of Days of Fever Following Therapy During Study Period (up to 6 Weeks)

The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion

Expression of GALGT2 as Demonstrated by Immunofluorescent Staining With Anti-CT Epitope Antibodies or WFA Lectin in Muscle Biopsy Sections at 120 Days Post Injection (Cohort 1) and 90 Days Post-injection (Cohort 2).

Intervention	Z-score (Mean)
Infliximab	-0.605
Placebo	-0.313

Intervention	mg/dL (Mean)
Infliximab	-6.6
Placebo	-3.6

Intervention	days (Median)
Infliximab	1
Placebo	2

Intervention	participants (Number)
Infliximab	11
Placebo	11

Percentage of fibers expressing GALGT2 in each biopsy sample. (NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)

GALGT2 Protein Expression Quantified by Western Blot and Assessed by Densitometry in Muscle Biopsy Tissue at 120 Days Post-injection (Cohort 1) and 90 Days Post-injection (Cohort 2)

Number of Unanticipated Grade III or Higher Treatment-Related Toxicities

Number of Meters Walked During the 6 Minute Walk Test

Intervention	Percentage of Positive Fibers (Number)
Cohort 1 (Minimal Efficacious Dose)	1.95
Cohort 2	1.72

Intervention	ng/mg total protein (Number)
Cohort 1 (Minimal Efficacious Dose)	12
Cohort 2	14.6

Intervention	events (Number)
Cohort 1 (Minimal Efficacious Dose)	0
Cohort 2	0

(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1) and Day 180 for both cohorts

Score of Muscle Function Using the The North Star Ambulatory Assessment (NSAA).

Intervention	meters (Number)
	Day 90 (Cohort 2) /Day 120 (Cohort 1)	Day 180
Cohort 1 (Minimal Efficacious Dose)	320	324
Cohort 2 (Minimal Efficacious Dose)	405	416

The NSAA provides a score between 0 and 34 where higher numbers represent greater muscle function. (NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24

Strength of the Bilateral Knee Flexors and Extensors During the Maximal Voluntary Isometric Strength Test.

Intervention	score on a scale (Number)
	Day 90/Day 120	Day 180	Month 12	Month 18	Month 24
Cohort 1 (Minimal Efficacious Dose)	16	14	10	6	2
Cohort 2	21	23	23	23	23

(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24

Time Taken to Walk 100 Meters During the 100 Meter Walk Test.

Intervention	kg (Number)
	Day 90/Day 120-Right Knee Extension	Day 90/Day 120-Right Knee Flexion	Day 90/Day 120- Left Knee Extension	Day 90/Day 120-Left Knee Flexion	Day 180-Right Knee Extension	Day 180-Right Knee Flexion	Day 180-Left Knee Extension	Day 180-Left Knee Flexion	Month 12-Right Knee Extension	Month 12-Right Knee Flexion	Month 12-Left Knee Extension	Month 12-Left Knee Flexion	Month 18-Right Knee Extension	Month 18-Right Knee Flexion	Month 18-Left Knee Extension	Month 18-Left Knee Flexion	Month 24-Right Knee Extension	Month 24-Right Knee Flexion	Month 24-Left Knee Extension	Month 24-Left Knee Flexion
Cohort 1 (Minimal Efficacious Dose)	7.42	6.06	8.78	6.12	7.13	6.1	8.66	6.69	7.49	5.67	7.5	5.32	4.55	6.11	4.96	6.26	5.06	4.41	6.93	4.17
Cohort 2	7.04	8.12	5.9	8.4	9.73	4.24	8.19	5.25	9.85	5.85	8.02	5.12	7.67	6.89	7.34	6.08	9.81	5.04	5.21	4.87

(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24

Time Taken to Walk 100 Meters During the 100 Meter Walk Test.

Intervention	seconds (Number)
	Day 90/Day 120	Day 180	Month 12	Month 18
Cohort 1 (Minimal Efficacious Dose)	98.2	110.9	144.5	167.8

(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24

Article	Year
Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis. Minerva medica, 2020, Volume: 111, Issue:2 Topics: Aspirin; Cause of Death; Heart Diseases; Humans; Myocardial Infarction; Outcome Assessment, Health C	2020
Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials. Coronary artery disease, 2019, Volume: 30, Issue:2 Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; He	2019
Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis. Journal of clinical pharmacology, 2013, Volume: 53, Issue:5 Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Dise	2013
Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke, 2014, Volume: 45, Issue:1 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Air Pollution; American Heart Association;	2014
Gastrointestinal bleeding in cardiac patients: epidemiology and evolving clinical paradigms. Current opinion in gastroenterology, 2014, Volume: 30, Issue:6 Topics: Age Factors; Anticoagulants; Aspirin; Gastrointestinal Hemorrhage; Heart Diseases; Hemostasis, Endos	2014
[Antithrombotic therapy in primary and secondary stroke prevention of cardiac patients and in acute stroke]. Orvosi hetilap, 2009, Feb-01, Volume: 150, Issue:5 Topics: Acute Disease; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Fibrinoly	2009
Secondary stroke prevention with antithrombotic drugs. Current vascular pharmacology, 2010, Volume: 8, Issue:1 Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Cyclooxygenase Inhibitors; Dipyridamole; Drug	2010
[Progress in clinical cardiology: surface electrocardiography, cardiovascular disease in women, and novel therapies]. Revista espanola de cardiologia, 2010, Volume: 63 Suppl 1 Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolyt	2010
What goes into a major acute coronary syndrome trial and what will future trials look like? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides;	2010
"Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest, 2011, Volume: 139, Issue:2 Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease	2011
Impact of antiplatelet therapy in heart disease. Advances in cardiology, 2012, Volume: 47 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio	2012
Unfractionated heparin in cardiology: redefining the standard of practice. Pharmacotherapy, 2004, Volume: 24, Issue:8 Pt 2 Topics: Angioplasty, Balloon; Aspirin; Drug Monitoring; Drug Therapy, Combination; Fibrinolytic Agents; Hear	2004
Exercise rehabilitation in heart disease: the real "polypill" for primary and secondary prevention. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2005, Volume: 64, Issue:2 Topics: Aspirin; Chronic Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise;	2005
New frontiers for cardiac risk assessment: C-reactive protein. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2006, Volume: 21, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarke	2006
[Prevention of thromboembolism in patients with atrial fibrillation]. MMW Fortschritte der Medizin, 2006, Apr-13, Volume: 148, Issue:15 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disea	2006
[Application of aspirin and other non-steroid anti-inflammatory drugs in cardiology. Cardiologist's expert opinion]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2006, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Heart Diseases; Humans; Risk Factors	2006
The big idea: the coxib crisis iron, aspirin and heart disease risk revisited. Journal of the Royal Society of Medicine, 2007, Volume: 100, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Heart Diseases; Human	2007
Con: continuation of aspirin/clopidogrel for cardiac surgery. Journal of cardiothoracic and vascular anesthesia, 2007, Volume: 21, Issue:4 Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Drug Therapy, Combination; Heart Diseases; Humans	2007
Pro: continuation of aspirin/clopidogrel for cardiac surgery. Journal of cardiothoracic and vascular anesthesia, 2007, Volume: 21, Issue:4 Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Heart Diseases; Humans; Platelet Aggregation Inhi	2007
Clinical implications of aspirin resistance. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:5 Topics: Aspirin; Cyclooxygenase 1; Drug Resistance; Enzyme Inhibitors; Heart Diseases; Humans; Ischemia; Pla	2007
How to prevent perioperative myocardial injury: the conundrum continues. American heart journal, 2007, Volume: 154, Issue:6 Topics: Adrenergic Agents; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Heart Diseases;	2007
Should patients on long-term warfarin take aspirin for heart disease? Cleveland Clinic journal of medicine, 2008, Volume: 75, Issue:3 Topics: Anticoagulants; Aspirin; Drug Synergism; Heart Diseases; Hemorrhage; Humans; Platelet Aggregation In	2008
Kawasaki disease: an overview. Current opinion in infectious diseases, 2008, Volume: 21, Issue:3 Topics: Aspirin; Child, Preschool; Heart Diseases; Humans; Immunoglobulins, Intravenous; Infant; Mucocutaneo	2008
Cardiogenic cerebral embolism. Comprehensive therapy, 1984, Volume: 10, Issue:9 Topics: Anticoagulants; Aspirin; Cardiac Surgical Procedures; Cerebral Hemorrhage; Cerebral Infarction; Dipy	1984
[Mucocutaneous lymph node syndrome or Kawasaki disease]. Revista clinica espanola, 1981, Nov-30, Volume: 163, Issue:4 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aspirin; Child; Child, Preschool; Female; Heart Dise	1981
Kawasaki syndrome (the mucocutaneous lymph node syndrome). Annual review of medicine, 1982, Volume: 33 Topics: Adrenal Cortex Hormones; Arthritis; Aspirin; Child; Child, Preschool; Female; Fever; Hawaii; Heart D	1982
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. Progress in clinical and biological research, 1982, Volume: 89 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary	1982
Evolving concepts in the pathogenesis and treatment of arterial thrombosis. The Mount Sinai journal of medicine, New York, 1995, Volume: 62, Issue:4 Topics: Adult; Angioplasty; Animals; Anticoagulants; Antithrombin III; Aspirin; Blood Coagulation Tests; Cor	1995
Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Texas Heart Institute journal, 1995, Volume: 22, Issue:3 Topics: Aspirin; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; H	1995
Stroke prevention. Archives of neurology, 1995, Volume: 52, Issue:4 Topics: Alcohol Drinking; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Di	1995
[Kawasaki disease]. Revue medicale de la Suisse romande, 1996, Volume: 116, Issue:10 Topics: Aspirin; Child; Child, Preschool; Heart Diseases; Heart Function Tests; Humans; Immunotherapy; Infan	1996
Role of transesophageal echocardiography in the management of thromboembolic stroke. The American journal of cardiology, 1997, Aug-28, Volume: 80, Issue:4C Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Cerebrovascular Disorde	1997
Travelling with heart disease. The Practitioner, 1998, Volume: 242, Issue:1583 Topics: Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dehydration; Diet; Heart Diseas	1998
Preventing heart disease and cancer. What randomized, primary-prevention studies show. Postgraduate medicine, 1999, Oct-15, Volume: 106, Issue:5 Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Coronary Disease; Female; Heart Diseases; Hu	1999
Long-term cardiac sequelae of Kawasaki disease. Current rheumatology reports, 2000, Volume: 2, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Catheterization; Child; Child, Pres	2000
[The best in 2000 on clinical pharmacology]. Archives des maladies du coeur et des vaisseaux, 2001, Volume: 94 Spec No 1 Topics: Aspirin; Cardiovascular Diseases; Forecasting; Heart Diseases; Heparin; Hormone Replacement Therapy;	2001
Reducing the risk: heart disease, stroke and aspirin. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2001, Volume: 84, Issue:8 Topics: Acute Disease; Aspirin; Blood Platelets; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart D	2001
Cardiac thromboembolism: evidence for role of platelets and value of platelet suppressant therapy. Advances in experimental medicine and biology, 1978, Volume: 102 Topics: Aspirin; Blood Platelets; Cell Survival; Clofibrate; Coronary Disease; Heart Diseases; Heart Valve D	1978
The pathophysiology of transient cerebral ischemic attacks. The Medical clinics of North America, 1979, Volume: 63, Issue:4 Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Cholesterol; Embolism; Endoc	1979
Antithrombotic therapy in atrial fibrillation. Chest, 1992, Volume: 102, Issue:4 Suppl Topics: Aspirin; Atrial Fibrillation; Embolism; Heart Diseases; Humans; Thrombolytic Therapy; Warfarin	1992
[Kawasaki syndrome]. Schweizerische medizinische Wochenschrift, 1990, Apr-14, Volume: 120, Issue:15 Topics: Aspirin; Child, Preschool; Coronary Aneurysm; Female; gamma-Globulins; Heart Diseases; Humans; Infan	1990
Eicosanoids and sudden cardiac death. Advances in prostaglandin, thromboxane, and leukotriene research, 1987, Volume: 17A Topics: Aspirin; Blood Platelets; Blood Vessels; Death, Sudden; Fatty Acids, Unsaturated; Heart Diseases; Hu	1987
Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA, 1988, Oct-21, Volume: 260, Issue:15 Topics: Angina, Unstable; Aspirin; Blood Pressure; Cholesterol; Exercise; Heart Diseases; Heart Failure; Hum	1988
Cardiac manifestations due to hypersensitivity. Annals of allergy, 1970, Volume: 28, Issue:6 Topics: Adams-Stokes Syndrome; Anaphylaxis; Angina Pectoris; Antigen-Antibody Complex; Arrhythmias, Cardiac;	1970

Article	Year
Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study. Scientific reports, 2023, 10-30, Volume: 13, Issue:1 Topics: Aspirin; Child; Cohort Studies; Heart Diseases; Humans; Immunoglobulins, Intravenous; Infant; Mucocu	2023
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. JAMA neurology, 2020, 01-01, Volume: 77, Issue:1 Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Carotid Stenosis; Double-Blind Method; Drug Therapy,	2020
Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis. Journal of clinical pharmacology, 2013, Volume: 53, Issue:5 Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Dise	2013
Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study. British journal of anaesthesia, 2016, Volume: 116, Issue:4 Topics: Aged; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Cohort Studies; Female; Heart Diseases; Humans;	2016
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease	2008
Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation, 2002, Aug-13, Volume: 106, Issue:7 Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Female; Gamm	2002
Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thrombosis and haemostasis, 2004, Volume: 92, Issue:6 Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Corona	2004
Protecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgery. Seminars in cardiothoracic and vascular anesthesia, 2006, Volume: 10, Issue:1 Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitor	2006
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. Progress in clinical and biological research, 1982, Volume: 89 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary	1982
Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy. European heart journal, 1993, Volume: 14, Issue:11 Topics: Age Factors; Aspirin; Echocardiography; Embolism; Heart Diseases; Heart Failure; Heart Ventricles; H	1993
An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. Stroke, 1996, Volume: 27, Issue:12 Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebral Infarction; Combined Modality Ther	1996
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998, Feb-10, Volume: 97, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In	1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998, Feb-10, Volume: 97, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In	1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998, Feb-10, Volume: 97, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In	1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998, Feb-10, Volume: 97, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In	1998
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Annals of internal medicine, 1998, Apr-15, Volume: 128, Issue:8 Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Drug Therapy,	1998
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer research, 1999, Dec-01, Volume: 59, Issue:23 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Anti	1999
Antithrombotic effects of abciximab. The American journal of cardiology, 2000, May-15, Volume: 85, Issue:10 Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Aspirin; Drug Therapy, Combination; Fibrinolyti	2000
[Risk factors for thromboembolism in patients with atrial fibrillation during treatment with aspirin: a multicenter, cooperative retrospective study. Research Group for Antiarrhythmic Drug Therapy]. Journal of cardiology, 2000, Volume: 35, Issue:5 Topics: Age Factors; Analysis of Variance; Aspirin; Atrial Fibrillation; Female; Heart Diseases; Humans; Mal	2000
Prognostic significance of elevated troponin I after percutaneous coronary intervention. Journal of the American College of Cardiology, 2002, Jun-05, Volume: 39, Issue:11 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Creatine Kinase; Creatine Kin	2002
Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study. Circulation, 1991, Volume: 84, Issue:2 Topics: Adult; Aged; Aspirin; Atenolol; Embolism; Female; Fibrinolytic Agents; Heart; Heart Diseases; Heart	1991
Usefulness of aspirin plus dipyridamole in reducing left ventricular thrombus formation in anterior wall acute myocardial infarction. The American journal of cardiology, 1989, Jan-01, Volume: 63, Issue:1 Topics: Aspirin; Blood Coagulation; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Therap	1989
Overview of completed sudden death trials: European experience. Cardiology, 1987, Volume: 74 Suppl 2 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Clinical Tri	1987
Effect of aspirin on brachial artery occlusion following brachial arteriotomy for coronary arteriography. Circulation, 1973, Volume: 47, Issue:3 Topics: Administration, Oral; Angiography; Arterial Occlusive Diseases; Aspirin; Blood Pressure; Brachial Ar	1973
Von Willebrand's disease. JAMA, 1971, May-10, Volume: 216, Issue:6 Topics: Adult; Aspirin; Blood Coagulation; Blood Coagulation Tests; Blood Transfusion; Chromosome Aberration	1971

Article	Year
Kawasaki disease in infants less than one year of age: an Italian cohort from a single center. BMC pediatrics, 2019, 09-07, Volume: 19, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Conjunctivitis; Delayed Diagnosis;	2019
[Dual Pathway Inhibition in Atherosclerosis - Which Patients Benefit?] Deutsche medizinische Wochenschrift (1946), 2019, Volume: 144, Issue:20 Topics: Aspirin; Atherosclerosis; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; Peripheral Arter	2019
Interaction between the effects of proton pump inhibitors and aspirin on gastric wall sestamibi uptake on myocardial perfusion imaging. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2021, Volume: 28, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Drug In	2021
Color Changes in the Fingers and Toes of an Infant. Clinical pediatrics, 2020, Volume: 59, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Color; Diagnosis, Differential; Echocardiography;	2020
Rivaroxaban reduces thromboxane induced platelet aggregation - the forgotten compass arm? Platelets, 2021, 11-17, Volume: 32, Issue:8 Topics: Aspirin; Chronic Disease; Drug Therapy, Combination; Heart Diseases; Humans; Platelet Aggregation; P	2021
Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases. Clinical hemorheology and microcirculation, 2021, Volume: 79, Issue:2 Topics: Aspirin; Blood Platelets; Heart Diseases; Humans; Platelet Aggregation; Platelet Aggregation Inhibit	2021
Preoperative platelet transfusions to reverse antiplatelet therapy for urgent non-cardiac surgery: an observational cohort study. Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Drug Administration Sche	2018
Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Acta pharmacologica Sinica, 2019, Volume: 40, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Female; H	2019
[Cerebral embolism in Duchenne muscular dystrophy after respiratory tract infection - Report of two cases]. Rinsho shinkeigaku = Clinical neurology, 2018, Oct-24, Volume: 58, Issue:10 Topics: Adult; Anticoagulants; Aspirin; Brain; Diffusion Magnetic Resonance Imaging; Echocardiography; Heart	2018
Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke. European journal of neurology, 2019, Volume: 26, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Cardiac Surgical Procedures; Ech	2019
[What's new regarding aspirin in cardiology ?] La Revue du praticien, 2018, Volume: 68, Issue:6 Topics: Aspirin; Cardiology; Heart Diseases; Humans; Platelet Aggregation Inhibitors	2018
The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. International journal of cardiology, 2019, 07-15, Volume: 287 Topics: Aged; Anterior Wall Myocardial Infarction; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response	2019
AHA recommendations for preventing heart disease in women. Nursing, 2013, Volume: 43, Issue:5 Topics: American Heart Association; Aspirin; Depression; Female; Global Health; Health Status Disparities; H	2013
Preoperative aspirin use and outcomes in cardiac surgery patients: a role of platelet function assessment. Annals of surgery, 2013, Volume: 258, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Surgical Procedures; Female; Heart	2013
Preoperative aspirin use in cardiac surgery. Annals of surgery, 2013, Volume: 258, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Surgical Procedures; Female; Heart	2013
Reply to letters: "Preoperative aspirin use and outcomes in cardiac surgery patients: a role of platelet function assessment" and "Preoperative aspirin use in cardiac surgery". Annals of surgery, 2013, Volume: 258, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Surgical Procedures; Female; Heart	2013
Chasing the ACE of hearts. BMJ case reports, 2013, Jun-25, Volume: 2013 Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Therapy, Combination; Electroca	2013
[The ARCTIC study]. Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:9 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Heart Diseases; Humans; Myocardi	2013
Aspirin protects some hearts better than others. It's in the genes. A biomarker can predict a person's response to this potentially lifesaving medication. DukeMedicine healthnews, 2013, Volume: 19, Issue:10 Topics: Aspirin; Blood Platelets; Genetic Markers; Genetic Predisposition to Disease; Heart Diseases; Humans	2013
Hybrid strategy for unstable patients with severe carotid and cardiac disease requiring surgery. Cardiology journal, 2015, Volume: 22, Issue:1 Topics: Aged; Angioplasty, Balloon; Anticoagulants; Aspirin; Cardiac Surgical Procedures; Carotid Artery Dis	2015
Ask the doctor. Is it okay to take both aspirin and ibuprofen therapies? Harvard health letter, 2014, Volume: 39, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Drug Interactions; Heart Diseas	2014
[Can perioperative aspirin prevent heart attacks?]. Medizinische Monatsschrift fur Pharmazeuten, 2014, Volume: 37, Issue:9 Topics: Aspirin; Heart Diseases; Humans; Intraoperative Complications; Perioperative Care; Platelet Aggregat	2014
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery. Thrombosis and haemostasis, 2015, Volume: 114, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub	2015
Low-dose aspirin for people with heart disease. Harvard heart letter : from Harvard Medical School, 2015, Volume: 26, Issue:2 Topics: Aspirin; Heart Diseases; Humans; Platelet Aggregation Inhibitors	2015
Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis. Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:2 Topics: Aspirin; Atrial Fibrillation; Clinical Laboratory Techniques; Coronary Artery Disease; Fibrinolysis;	2016
Use of preoperative aspirin in combined coronary and valve operations. Surgery, 2016, Volume: 160, Issue:6 Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Female; Fibrinolytic Agents; Heart Disease	2016
Antiaggregant and anticoagulant therapy of free-floating thrombus in left atrium. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2008, Jun-07, Volume: 8, Issue:3 Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Dyspnea; Echocardiography, Tra	2008
Safety and efficacy of clopidogrel in children with heart disease. The Journal of pediatrics, 2008, Volume: 153, Issue:1 Topics: Adolescent; Aspirin; Child; Child, Preschool; Clopidogrel; Female; Heart Diseases; Hemorrhage; Human	2008
Apical thrombus in a patient with takotsubo cardiomyopathy. Journal of cardiovascular medicine (Hagerstown, Md.), 2008, Volume: 9, Issue:8 Topics: Administration, Oral; Aspirin; Coronary Angiography; Diagnosis, Differential; Drug Therapy, Combinat	2008
[Congestive cardiomyopathy and left intraventricular thrombus as a manifestation of Churg-Strauss syndrome]. Kardiologia polska, 2008, Volume: 66, Issue:7 Topics: Adult; Aspirin; Cardiomyopathy, Dilated; Churg-Strauss Syndrome; Female; Heart Diseases; Heparin, Lo	2008
Exodontia and antiplatelet therapy. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2008, Volume: 66, Issue:10 Topics: Administration, Oral; Aspirin; Bleeding Time; Dental Care for Chronically Ill; Heart Diseases; Hemos	2008
Antiplatelets for stroke prevention: implications of the PRoFESS trial. Stroke, 2009, Volume: 40, Issue:5 Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy,	2009
Transient left ventricular apical ballooning complicated by a mural thrombus and outflow tract obstruction in a patient with pheochromocytoma. Texas Heart Institute journal, 2008, Volume: 35, Issue:4 Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Angina Pectoris; Anticoagulants; Aspirin; Che	2008
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. American heart journal, 2009, Volume: 157, Issue:6 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Heart Diseases; Humans; M	2009
A single pill for prevention? Harvard heart letter : from Harvard Medical School, 2009, Volume: 19, Issue:11 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Folic Acid; Heart Dise	2009
Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses. The Journal of heart valve disease, 2009, Volume: 18, Issue:6 Topics: Aged; Aortic Valve; Aspirin; Blood Platelets; Clopidogrel; Drug Combinations; Female; Follow-Up Stud	2009
Platelet function analysis with two different doses of aspirin. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:4 Topics: Analysis of Variance; Aspirin; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Hea	2010
Optimal antithrombotic therapy in patients receiving long-term oral anticoagulation requiring percutaneous coronary intervention: "triple therapy" or "triple threat". Chest, 2011, Volume: 139, Issue:2 Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease	2011
Protect your heart during dental work. Don't stop taking aspirin, Plavix, or any other antiplatelet before dental work without asking your cardiologist. Harvard heart letter : from Harvard Medical School, 2011, Volume: 21, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Dental Care for Chronically Ill; Hear	2011
The use of contrast echo to clear the left atrial appendage. Acute cardiac care, 2011, Volume: 13, Issue:2 Topics: Aspirin; Atrial Appendage; Clopidogrel; Contrast Media; Drug Therapy, Combination; Echocardiography;	2011
Outpatient aspirin desensitization for patients with aspirin hypersensitivity and cardiac disease. Critical pathways in cardiology, 2011, Volume: 10, Issue:1 Topics: Adult; Aged; Aspirin; Clinical Protocols; Desensitization, Immunologic; Drug Hypersensitivity; Femal	2011
[Kawasaki disease in older children and young adults: 10 years of experience in Marseille, France]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2011, Volume: 18, Issue:7 Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, No	2011
Reduction of thienopyridine-associated bleeding using multiple electrode whole-blood aggregometry. The Annals of thoracic surgery, 2011, Volume: 92, Issue:2 Topics: Adenosine Diphosphate; Aspirin; Cardiopulmonary Bypass; Electrodes; Heart Diseases; Humans; Platelet	2011
Thrombus formation on a left atrial appendage closure device. Circulation, 2011, Oct-04, Volume: 124, Issue:14 Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Equipment Design;	2011
Preoperative aspirin use and outcomes in cardiac surgery patients. Annals of surgery, 2012, Volume: 255, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Surgical Procedures; Female;	2012
Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. The American journal of cardiology, 2012, Aug-15, Volume: 110, Issue:4 Topics: Aged; Aspirin; Blood Transfusion; Cardiovascular Surgical Procedures; Case-Control Studies; Coronary	2012
Perioperative use of aspirin for patients undergoing carotid endarterectomy. VASA. Zeitschrift fur Gefasskrankheiten, 2012, Volume: 41, Issue:4 Topics: Administration, Oral; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Drug Administration	2012
Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease. The Canadian journal of cardiology, 2013, Volume: 29, Issue:4 Topics: Adipocytes; Adipose Tissue; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blotting, Weste	2013
Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:11 Topics: Aged; Aspirin; Cross-Sectional Studies; Drug Utilization; Female; Heart Diseases; HIV Infections; Hu	2012
Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. Journal of applied toxicology : JAT, 2014, Volume: 34, Issue:2 Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Cardiotoxins; Clomipramine; Cyclophosphamide; Disease	2014
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). European heart journal, 2002, Volume: 23, Issue:15 Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Australia; Canada; E	2002
Comparison of secondary prevention of heart disease in Europe: lifestyle getting worse, therapy getting better in Ireland. Irish medical journal, 2002, Volume: 95, Issue:9 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Mellitus, T	2002
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?). Gastroenterology, 2003, Volume: 124, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru	2003
Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. American heart journal, 2003, Volume: 145, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography, Tran	2003
Ibuprofen interferes with aspirin's benefits. Health news (Waltham, Mass.), 2003, Volume: 9, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Heart Diseases; Humans; Ibuprof	2003
Practice tips. Preventing heart disease with ASA. Canadian family physician Medecin de famille canadien, 2003, Volume: 49 Topics: Aspirin; Family Practice; Heart Diseases; Humans; Platelet Aggregation Inhibitors; Practice Guidelin	2003
Aspirin for everything? Consumer reports, 2003, Volume: 68, Issue:7 Topics: Adult; Alzheimer Disease; Aspirin; Clinical Trials as Topic; Heart Diseases; Humans; Neoplasms	2003
Regression of intracardiac heparin-induced thrombosis after aortic root surgery. The Annals of thoracic surgery, 2003, Volume: 76, Issue:2 Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug	2003
Cardiology patient page. Antiplatelet therapy. Circulation, 2003, Aug-19, Volume: 108, Issue:7 Topics: Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Heart Diseases; Humans; Platelet Aggregati	2003
[Stroke is not equal to stroke. Keep track of the causes]. MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1 Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S	2003
The use of acetylsalicylic acid in the treatment of the arthritic patient with far advanced cardiovascular disease. The West Virginia medical journal, 1958, Volume: 54, Issue:4 Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Heart Diseases; Humans	1958
CAUSAL INFLUENCES IN HAEMATEMESIS AND MELAENA. Gut, 1965, Volume: 6 Topics: Alcoholic Beverages; Arteriosclerosis; Aspirin; Blood Group Antigens; Duodenal Ulcer; Genetics, Medi	1965
ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. Lancet (London, England), 1965, May-15, Volume: 1, Issue:7394 Topics: Aspirin; Brain Diseases; Carbohydrate Metabolism; Coma; Fatty Liver; Heart Diseases; Humans; Kidney	1965
Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation, 2003, Sep-23, Volume: 108, Issue:12 Topics: Age Factors; Aspirin; C-Reactive Protein; Cholesterol; Diabetes Mellitus; Female; Heart Diseases; Hu	2003
A "polypill" a day keeps heart disease away. Health news (Waltham, Mass.), 2003, Volume: 9, Issue:9 Topics: Antihypertensive Agents; Aspirin; Drug Combinations; Folic Acid; Heart Diseases; Humans; Hypolipidem	2003
Aspirin withdrawal increases risk of heart problems. Lancet (London, England), 2003, Nov-08, Volume: 362, Issue:9395 Topics: Aspirin; Coronary Disease; Heart Diseases; Humans; Substance Withdrawal Syndrome	2003
The Polypill: a simple "cure" for heart disease and stroke? Harvard men's health watch, 2004, Volume: 8, Issue:8 Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Drug Combinations; Folic Acid; Heart Dis	2004
[A 78-year-old man with anterior chest pain]. Journal of cardiology, 2004, Volume: 43, Issue:6 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Biomarkers; Cardiomyopathie	2004
Rupture of a giant coronary artery aneurysm due to Kawasaki disease. The Annals of thoracic surgery, 2004, Volume: 78, Issue:2 Topics: Anticoagulants; Aspirin; Cardiac Tamponade; Child, Preschool; Combined Modality Therapy; Coronary An	2004
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 2004, Oct-26, Volume: 110, Issue:17 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Coronary Aneurysm; Coronary Ang	2004
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics, 2004, Volume: 114, Issue:6 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Coronary Aneurysm; Coronary Ang	2004
Prophylactic anticoagulation following the Fontan operation. Heart (British Cardiac Society), 2005, Volume: 91, Issue:7 Topics: Adult; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Fontan Procedure; Heart Diseases; Humans; Post	2005
By the way, doctor. I'm confused. I've read your articles about heart disease being caused by inflammation. If the COX-2 drugs are anti-inflammatory, why do they seem to make heart disease worse, not better? Harvard health letter, 2005, Volume: 30, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Female; Heart Diseases;	2005
Should aspirin be discontinued before coronary artery bypass surgery? Circulation, 2005, Aug-16, Volume: 112, Issue:7 Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox	2005
Should aspirin be discontinued before coronary artery bypass surgery? Circulation, 2005, Aug-16, Volume: 112, Issue:7 Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox	2005
Should aspirin be discontinued before coronary artery bypass surgery? Circulation, 2005, Aug-16, Volume: 112, Issue:7 Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox	2005
Should aspirin be discontinued before coronary artery bypass surgery? Circulation, 2005, Aug-16, Volume: 112, Issue:7 Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox	2005
What to take for pain now. New warnings abound, but there are good alternatives. Heart advisor, 2005, Volume: 8, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Cyclooxygenase Inhibitors; Hear	2005
Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function? Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:4 Topics: Adenosine Diphosphate; Adult; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Clopidogrel; Fl	2005
Drug combinations best for heart disease. Harvard heart letter : from Harvard Medical School, 2005, Volume: 16, Issue:1 Topics: Adrenergic beta-Antagonists; Aspirin; Drug Combinations; Heart Diseases; Humans; Hydroxymethylglutar	2005
For the patient. Use of aspirin lower among ethnic populations. Ethnicity & disease, 2005,Autumn, Volume: 15, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Heart Diseases; Hispanic or Latino;	2005
Drug testing. Massive trial of Celebrex seeks to settle safety concerns. Science (New York, N.Y.), 2005, Dec-23, Volume: 310, Issue:5756 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Confounding Factors, Epidemiologic; Cyc	2005
Evaluating and treating cardiometabolic risk factors: a case discussion. Pharmacotherapy, 2006, Volume: 26, Issue:5 Pt 2 Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diet; Dyslipidemias; Exercise; Female; Heart Dise	2006
Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation, 2006, Jun-06, Volume: 113, Issue:22 Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort S	2006
Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. Journal of cardiovascular pharmacology, 2006, Volume: 48, Issue:2 Topics: Adult; Aged; Aspirin; Drug Resistance; Female; Heart Diseases; Humans; Male; Middle Aged; Platelet A	2006
[When ASS, when anticoagulants?]. MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Clopidogrel; Female; Heart Disease	2006
Antithrombotic therapy and predilection for cerebellar hemorrhage. Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 23, Issue:2-3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis; Aspirin; Blo	2007
New guidelines on preventing heart disease in women propose aspirin for all aged over 65. BMJ (Clinical research ed.), 2007, Mar-03, Volume: 334, Issue:7591 Topics: Aged; Aspirin; Female; Heart Diseases; Humans; Platelet Aggregation Inhibitors	2007
Combined rTPA and aspirin therapy for intracardiac thrombosis in neonates. Arquivos brasileiros de cardiologia, 2007, Volume: 88, Issue:5 Topics: Aspirin; Diseases in Twins; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heart Diseases;	2007
Guidelines offer women a change of heart. Focusing on prevention is the best way to halt heart disease in women. Harvard heart letter : from Harvard Medical School, 2007, Volume: 17, Issue:11 Topics: Aspirin; Estrogens; Female; Fibrinolytic Agents; Guidelines as Topic; Heart Diseases; Humans; Platel	2007
[Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Interactions; Hear	2006
Treatment of massive cardiac thrombi in a patient with protein C and protein S deficiency. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:7 Topics: Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Child, Preschool; Female; Fibrinolytic Agents; Hea	2007
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido	2008
Hemorheological background of acetylsalicylic acid resistance. Clinical hemorheology and microcirculation, 2008, Volume: 38, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Blood Viscosity; Cerebrovascular Disorders; Erythrocyte Aggregation;	2008
[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation]. Kardiologiia, 2007, Volume: 47, Issue:6 Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Female; F	2007
[Kawasaki disease]. La Revue du praticien, 2007, Nov-30, Volume: 57, Issue:18 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Diagnosis, Differential; Disease Pro	2007
Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. The Journal of heart valve disease, 2008, Volume: 17, Issue:1 Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Fol	2008
[Role of medical treatment in the rehabilitation of the coronary patient]. Revue medicale de la Suisse romande, 1981, Volume: 101, Issue:1 Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Heart Diseases; Humans; Myoc	1981
Failure of aspirin to prevent incorporation of indium-111 labelled platelets into cardiac thrombi in man. Lancet (London, England), 1981, Aug-29, Volume: 2, Issue:8244 Topics: Aspirin; Blood Platelets; Heart Aneurysm; Heart Diseases; Heart Ventricles; Humans; Indium; Platelet	1981
Cardiovascular complications of mucocutaneous lymph node syndrome. Pediatric clinics of North America, 1984, Volume: 31, Issue:6 Topics: Aneurysm; Aspirin; Child, Preschool; Coronary Disease; Echocardiography; Female; Heart Diseases; Hea	1984
Diagnosis and management of ischemic stroke. Part I.--Threatened stroke and its management. Current problems in cardiology, 1983, Volume: 8, Issue:5 Topics: Anticoagulants; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Carotid Artery Thrombosis; Cerebral A	1983
[Case of mitral stenosis with regression and elimination of left atrial thrombus after combined therapy of urokinase, dipyridamole and aspirin]. Kokyu to junkan. Respiration & circulation, 1983, Volume: 31, Issue:11 Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Echocardiography; Female; Heart Atria; Heart	1983
Kawasaki syndrome: an update. Hospital practice (Hospital ed.), 1982, Volume: 17, Issue:3 Topics: Adult; Aspirin; Child; Child, Preschool; Coronary Angiography; Diagnosis, Differential; Follow-Up St	1982
[Studies on antiplatelet therapy of low dosage of aspirin from the view point of its effect on platelet aggregation (author's transl)]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1981, Volume: 18, Issue:6 Topics: Adult; Aged; Aspirin; Female; Heart Diseases; Humans; Male; Middle Aged; Platelet Aggregation	1981
Power and temperature guided radiofrequency catheter ablation of the right atrium in pigs. Pacing and clinical electrophysiology : PACE, 1994, Volume: 17, Issue:10 Topics: Animals; Aspirin; Catheter Ablation; Heart Atria; Heart Diseases; Heparin; Lung Injury; Postoperativ	1994
[Transthoracic and transesophageal follow-up in patients with left atrial thrombosis]. Zeitschrift fur Kardiologie, 1994, Volume: 83, Issue:7 Topics: Aged; Aspirin; Combined Modality Therapy; Echocardiography; Echocardiography, Doppler, Color; Echoca	1994
[Left ventricular thrombosis after acute myocardial infarction: relationship with thrombolytic therapy and the patency of the "guilty" vessel]. Giornale italiano di cardiologia, 1994, Volume: 24, Issue:3 Topics: Adult; Aged; Aspirin; Female; Heart Diseases; Heart Ventricles; Heparin; Humans; Male; Middle Aged;	1994
Left atrial thrombi despite anticoagulant and antiplatelet therapy. Clinical cardiology, 1994, Volume: 17, Issue:7 Topics: Aged; Aspirin; Atrial Fibrillation; Dilatation, Pathologic; Echocardiography; Echocardiography, Tran	1994
From the Food and Drug Administration. JAMA, 1993, Dec-08, Volume: 270, Issue:22 Topics: Aspirin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Labeling; Drugs, Investigational;	1993
Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. Stroke, 1994, Volume: 25, Issue:4 Topics: Adult; Aged; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Echocardiography, Transesophag	1994
Thrombolytic therapy and intravenous heparin in acute myocardial infarction do not affect the incidence of left ventricular mural thrombus formation. American heart journal, 1994, Volume: 127, Issue:5 Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Heart Diseases; Heart Ventricles; Heparin; Humans;	1994
Adverse effect of warfarin in acute myocardial infarction: increased left ventricular thrombus formation in patients not treated with high-dose heparin. European heart journal, 1993, Volume: 14, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Dru	1993
Dynamics of left ventricular thrombi in patients with acute anterior myocardial infarction treated with thrombolytics. Coronary artery disease, 1995, Volume: 6, Issue:9 Topics: Adult; Aged; Aspirin; Female; Fibrinolytic Agents; Heart Diseases; Heart Ventricles; Humans; Male; M	1995
Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era. Heart (British Cardiac Society), 1996, Volume: 75, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Echocardiography; Female; Follow-Up Studies; Heart Diseases	1996
Gastric safety and enteric-coated aspirin. Lancet (London, England), 1997, Feb-08, Volume: 349, Issue:9049 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Hemorrhage; Heart Diseases; Human	1997
Prevalence of aspirin use to prevent heart disease--Wisconsin, 1991, and Michigan, 1994. MMWR. Morbidity and mortality weekly report, 1997, Jun-06, Volume: 46, Issue:22 Topics: Aged; Aspirin; Drug Utilization; Female; Heart Diseases; Humans; Male; Michigan; Middle Aged; Preval	1997
Aspirin in in-flight emergencies. Annals of internal medicine, 1998, Feb-15, Volume: 128, Issue:4 Topics: Aerospace Medicine; Aircraft; Aspirin; Emergencies; Heart Diseases; Humans; Travel	1998
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Circulation, 1998, Feb-24, Volume: 97, Issue:7 Topics: Animals; Aspirin; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Fibrinoly	1998
[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy]. Journal of cardiology, 1998, Volume: 31, Issue:4 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dipyridamole; Female; Heart Diseases; Humans; Male; Mi	1998
Kawasaki disease in a paediatric hospital in Riyadh. Annals of tropical paediatrics, 1998, Volume: 18, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Diagnosis, Differential;	1998
Warfarin or aspirin: both or others? The Medical journal of Australia, 1999, Sep-20, Volume: 171, Issue:6 Topics: Aged; Anticoagulants; Aspirin; Embolism; Female; Heart Diseases; Humans; Male; Middle Aged; Platelet	1999
Re: The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3,575 hospitalized patients with atrial fibrillation. 1998;14:695-702. The Canadian journal of cardiology, 2000, Volume: 16, Issue:1 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Heart Diseases; Humans; Pra	2000
Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke, 2000, Volume: 31, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease;	2000
The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. Journal of the American College of Cardiology, 2000, Volume: 35, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Interactions; Heart Diseases; Humans; Platel	2000
[Prevention of thromboembolic disease in patients with heart disease]. Atencion primaria, 2000, Sep-30, Volume: 26, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; Dipyridamole	2000
Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:10 Topics: Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Aspirin; CD4-Positive T-Lym	2001
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997, Volume: 97, Issue:6 Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antibodies, Antiphospholipid; Anticoagulants; Anti	1997
Kawasaki disease--Indian perspective. Indian journal of pediatrics, 2001, Volume: 68, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Conjunctival Diseases; Heart Dis	2001
Aspirin use associated with lowered risk of all-cause mortality in patients with known or suspected heart disease. Circulation, 2001, Sep-18, Volume: 104, Issue:12 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Echocardiography; Heart Diseases; Hum	2001
Aspirin: little pill, big potential. Health news (Waltham, Mass.), 2002, Volume: 8, Issue:3 Topics: Aspirin; Heart Diseases; Humans; Practice Guidelines as Topic; Risk Factors; United States	2002
Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Archives of disease in childhood, 2002, Volume: 86, Issue:4 Topics: Adrenal Cortex Hormones; Aspirin; Contraindications; Heart Diseases; Humans; Immunoglobulins, Intrav	2002
MA hospitals go online to improve guideline compliance. Data strategies & benchmarks : the monthly advisory for health care executives, 2002, Volume: 6, Issue:4 Topics: American Heart Association; Antihypertensive Agents; Aspirin; Guideline Adherence; Heart Diseases; H	2002
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. The New England journal of medicine, 2002, May-16, Volume: 346, Issue:20 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Heart Diseases; Humans;	2002
Psotcardiotomy syndrome: pathogenesis and management. Hospital practice, 1976, Volume: 11, Issue:9 Topics: Adrenal Cortex Hormones; Antibodies; Antigen-Antibody Complex; Aspirin; Heart Diseases; Hemorrhage;	1976
Kawasaki disease is diagnosed in Virginia. Virginia medical, 1978, Volume: 105, Issue:10 Topics: Adolescent; Aspirin; Child; Child, Preschool; Coronary Angiography; Diagnosis, Differential; Female;	1978
[Side and toxic effects of salicylates]. La Clinica terapeutica, 1976, Oct-31, Volume: 79, Issue:2 Topics: Aspirin; Chemical and Drug Induced Liver Injury; Female; Heart Diseases; Humans; Kidney Diseases; Ma	1976
[The use of acetylsalicylic acid as a platelet antiaggregant]. Arquivos brasileiros de cardiologia, 1992, Volume: 59, Issue:2 Topics: Adolescent; Adult; Aged; Aspirin; Child; Drug Evaluation; Heart Diseases; Hemostasis; Humans; Hypert	1992
Hemorrhaging heart patients. Journal of the American College of Cardiology, 1992, Volume: 19, Issue:1 Topics: Aspirin; Gastrointestinal Hemorrhage; Heart Diseases; Humans; Tablets, Enteric-Coated	1992
[A case of hypereosinophilic syndrome followed by bronchial asthma, intraventricular thrombus, and duodenitis]. Nihon Kyobu Shikkan Gakkai zasshi, 1991, Volume: 29, Issue:10 Topics: Adult; Aspirin; Asthma; Duodenitis; Eosinophilia; Heart Diseases; Humans; Male; Myocarditis; Prednis	1991
Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation, 1991, Volume: 84, Issue:2 Topics: Angioplasty, Balloon; Animals; Arteries; Aspirin; Dipyridamole; Fibrinolytic Agents; Heart Diseases;	1991
Aspirin. Scientific American, 1991, Volume: 264, Issue:1 Topics: Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Disorders; Cell Membr	1991
Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction. American heart journal, 1991, Volume: 122, Issue:1 Pt 1 Topics: Aged; Aspirin; Female; Heart Diseases; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Inf	1991
[Kawasaki disease. Report of two cases]. Anales espanoles de pediatria, 1990, Volume: 33, Issue:1 Topics: Aspirin; Child, Preschool; Female; Heart Diseases; Humans; Infant; Male; Mucocutaneous Lymph Node Sy	1990
Duration of therapy in rheumatic fever without carditis. The Journal of the Association of Physicians of India, 1990, Volume: 38, Issue:9 Topics: Acute Disease; Aspirin; Drug Administration Schedule; Heart Diseases; Humans; Rheumatic Fever	1990
Does antiplatelet therapy enhance myocardial salvage after coronary reperfusion? Journal of the American College of Cardiology, 1990, Volume: 15, Issue:7 Topics: Animals; Aspirin; Dogs; Fibrinolytic Agents; Heart Diseases; Hemodynamics; Hemorrhage; Myocardial In	1990
Kawasaki syndrome: still a fascinating enigma. Hospital practice (Office ed.), 1989, Oct-15, Volume: 24, Issue:10 Topics: Aspirin; Child; Child, Preschool; Coronary Aneurysm; Heart Diseases; Humans; Immunization, Passive;	1989
[A case of mitral stenosis with left atrial thrombus arose and reduced in a short-term]. Kokyu to junkan. Respiration & circulation, 1989, Volume: 37, Issue:5 Topics: Aspirin; Female; Heart Atria; Heart Diseases; Humans; Middle Aged; Mitral Valve Stenosis; Thrombosis	1989
Coronary thrombolysis. The Medical journal of Australia, 1989, Jan-16, Volume: 150, Issue:2 Topics: Aged; Aspirin; Heart Diseases; Humans; Myocardial Infarction; Streptokinase; Thrombosis	1989
[Effect of long-term anticoagulant and antithrombocytic therapy on the size of intracavitary thrombus and the incidence of thromboembolic complications in patients with acute myocardial infarction]. Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR, 1989, Volume: 12, Issue:1 Topics: Aspirin; Heart Diseases; Humans; Myocardial Infarction; Phenindione; Thromboembolism; Thrombosis; Ti	1989
Detection and management of cardiac involvement in the Kawasaki syndrome. Pediatric annals, 1987, Volume: 16, Issue:8 Topics: Aspirin; Child, Preschool; Coronary Aneurysm; Female; Heart Diseases; Humans; Immunization, Passive;	1987
Preventing coronary involvement in Kawasaki disease. JAMA, 1986, Jan-10, Volume: 255, Issue:2 Topics: Aspirin; Child; Heart Diseases; Humans; Mucocutaneous Lymph Node Syndrome	1986
[Neuropsychiatry in 1973]. La Revue du praticien, 1973, Apr-21, Volume: 23, Issue:23 Topics: Aspirin; Bipolar Disorder; Dipyridamole; Heart Diseases; Humans; Hydrocephalus; Hypoxia, Brain; Isch	1973

aspirin and Cardiac Diseases

Research Excerpts

Research

Studies (213)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

All-cause Mortality

All-cause Mortality in LTOLE Part

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Change From Baseline in Left Anterior Descending Coronary Artery Outcomes at Week 2 by Treatment Arm

Change in C-reactive Protein (CRP) From Baseline at 24 Hours After Completion of Intravenous Immunoglobulin (IVIG) by Study Arm.

Number of Days of Fever Following Therapy During Study Period (up to 6 Weeks)

The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion

Expression of GALGT2 as Demonstrated by Immunofluorescent Staining With Anti-CT Epitope Antibodies or WFA Lectin in Muscle Biopsy Sections at 120 Days Post Injection (Cohort 1) and 90 Days Post-injection (Cohort 2).

GALGT2 Protein Expression Quantified by Western Blot and Assessed by Densitometry in Muscle Biopsy Tissue at 120 Days Post-injection (Cohort 1) and 90 Days Post-injection (Cohort 2)

Number of Unanticipated Grade III or Higher Treatment-Related Toxicities

Number of Meters Walked During the 6 Minute Walk Test

Score of Muscle Function Using the The North Star Ambulatory Assessment (NSAA).

Strength of the Bilateral Knee Flexors and Extensors During the Maximal Voluntary Isometric Strength Test.

Time Taken to Walk 100 Meters During the 100 Meter Walk Test.

Time Taken to Walk 100 Meters During the 100 Meter Walk Test.

Reviews

Trials

Other Studies